Onyx spurns Amgen takeover bid, puts itself up for sale
This article was originally published in Scrip
Executive Summary
Onyx Pharmaceuticals said it rejected Amgen’s unsolicited takeover offer for almost $9 billion and will seek out other companies that may be interested in acquiring the cancer drug specialist.